Set to take place at MBC Media Center Public Hall in Sangam-dong, Mapo-gu in Seoul, the K-drama event will see TV host Kim ...
MBC’s history dates back to 1983. That year, the federal government created a program to give money to northern Canadian organizations that wanted to start up TV and radio stations to broadcast in ...
Korean actor Lee Je-hoon’s “Taxi Driver 3” emerged as the No. 1 favorite broadcast video program in December in South Korea. Polling firm Gallup ...
Sportschosun on MSN
Tzuyu, I'm honestly full. I succeeded in eating despite the crisis
MBC 'Omniscient Interfere Viewpoint'Tzuyang's Sapporo-style World and Choi Hong-man's Miniature World Survival Story made a ...
Athira has acquired an exclusive global license (excluding Asia and certain countries in the Middle East) from Sermonix Pharmaceuticals, Inc. for rights to develop and commercialize lasofoxifene, a ...
SHINee’s Key will step down from all current programmes after being linked to allegations involving unauthorised medical ...
Sportschosun on MSN
Park Na-rae, 'I Live Alone in a Vacation.' Lowest ratings this year...a controversial aftermath
MBC entertainment program 'I Live Alone' has suffered the aftermath of Park Na-rae's controversy.According to viewer rating ...
The program has been under scrutiny for years and the subject of a Channel 11 investigation after we noticed city-funded demolitions dropped dramatically in 2024.
My best advice for anyone recently diagnosed with MBC is to keep a notebook and take someone with you to every appointment. There’s just so much information. Even if you’ve been through a previous ...
Trodelvy did not show statistically significant PFS improvement over chemotherapy in hormone-receptor-positive/HER2-negative breast cancer post-endocrine therapy. Investigator-assessed PFS showed a ...
Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) ...
Presentation Title: The ADELA study: A Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA)+ Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2-Advanced Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results